Cancer Stem Cell News Volume 9.13 | Apr 08 2020

TOP STORY

Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas

Scientists found that glioblastoma stem cells within the glioblastoma cerebral organoids model were enriched for a neural progenitor-like cell subpopulation and recapitulated the cellular states and their plasticity found in the corresponding primary parental tumors. [Cancer Discov] Abstract | Full Article

(Ranked by impact factor of the journal)

H3K79me2/3 Controls Enhancer-Promoter Interactions and Activation of the Pan-Cancer Stem Cell Marker PROM1/CD133 in MLL-AF4 Leukemia Cells

Scientists demonstrated that aberrant prominin-1 (PROM1)/CD133 expression was essential for leukemic cell growth, mediated by direct binding of MLL-AF4. [Leukemia] Full Article

Cullin-7 (CUL7) Is Overexpressed in Glioma Cells and Promotes Tumorigenesis via NF-κB Activation

RNA silencing was performed using siRNA or lentiviral constructs in U87MG and U251 glioma cell lines and GSC267 glioma stem cells. Gene silencing of CUL7 in U87MG and U251 cells significantly inhibited tumor growth, invasion and migration in vitro and in vivo. [J Exp Clin Cancer Res] Full Article

Chemotherapy Exacerbates Ovarian Cancer Cell Migration and Cancer Stem Cell-Like Characteristics through GLI1

Chemotherapy was found to not only kill tumor cells, but also trigger the induction of CSC-like traits and the migration of ovarian cancer cells. [Br J Cancer] Abstract

Immunomodulatory Molecules On Lung Cancer Stem Cells from Lymph Nodes Aspirates

Investigators reported the higher frequency of mature tumor cells and CSCs expressing the investigated immunomodulating molecules in metastatic lymph nodes than in nonmetastatic. [Cancers] Full Article

Novel C-Terminal Heat Shock Protein 90 Inhibitors Target Breast Cancer Stem Cells and Block Migration, Self-Renewal, and Epithelial-Mesenchymal Transition

The authors hypothesized that the novel C-terminal HSP90 inhibitors KU711 and KU758 could target tumor initiating cells and represented a promising strategy for overcoming metastasis. [Mol Oncol] Abstract

Ribosomal Protein S6 Promotes Stem-Like Characters in Glioma Cells

The authors investigated the mechanism underlying stemness acquisition in glioblastoma multiform (GBM) cells by focusing on 40S ribosomal protein S6 (RPS6). RPS6 was significantly upregulated in high-grade glioma and localized at perivascular, perinecrotic, and border niches in GBM tissues. [Cancer Sci] Abstract

CD45^dimCD34⁺CD38^–CD133⁺ Cells Have the Potential As Leukemic Stem Cells in Acute Myeloid Leukemia

Leukemia stem cells were prominently detected in the bone marrow cells (BMCs) isolated from patients with acute myeloid leukemia and chronic myeloid leukemia, but rarely in BMCs isolated from patients with diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, acute lymphocytic leukemia, chronic lymphocytic leukemia, and Hodgkin lymphoma. [BMC Cancer] Full Article

Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News.

New Insights Into the Functions of Cox-2 in Skin and Esophageal Malignancies

The authors review experimental evidence aiming to define the origins of skin and esophageal cancers and discuss how cyclooxygenase-2 (Cox-2) contributes to tumorigenesis and differentiation. [Exp Mol Med] Full Article

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China

Ascentage Pharma announced that it has received approval from the Center for Drug Evaluation of the China National Medical Products Administration for the Phase Ib/II study of APG-2575, the company’s novel Bcl-2-selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. [Ascentage Pharma (PR Newswire Association LLC)] Press Release

Gracell Announces China MNPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Gracell Biotechnologies Co. announced that China National Medical Products Administration has accepted Gracell’s Investigational New Drug application for GC007g, a donor-derived anti-CD19 chimeric antigen receptor cell therapy. [Gracell Biotechnologies Co. (PR Newswire Association LLC)] Press Release

Ryvu Therapeutics Receives Orphan Drug Designation from FDA For SEL120 to Treat Acute Myeloid Leukemia

Ryvu Therapeutics announced that the FDA has granted an orphan drug designation to Ryvu’s SEL120, for the treatment of patients with acute myeloid leukemia. [Ryvu Therapeutics] Press Release

Early-Career Scientists at Critical Career Junctures Brace for Impact of COVID-19

For some scientists, the shutdowns have made it more challenging for them to complete their work. But for others, they come at a critical juncture in the scientist’s career, threatening to derail or delay a major event along their professional path-a small slice of the human suffering and inconvenience that COVID-19 has caused. [ScienceInsider] Editorial

Safely Conducting Essential Research in the Face of COVID-19

Some scientists can’t simply stop going to their laboratories – especially not those who are overseeing clinical trials that could offer life-saving vaccines and therapies, particularly against the new coronavirus. And some research activities must continue even in the face of a shutdown. [Nature News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Breast Cancer Stem Cell Research (North Carolina Central University)

Postdoctoral Positions – DNA Repair in Leukemia (Temple University School of Medicine)

Associate Professor – Regenerative Medicine (Guangzhou Regenerative Medicine and Health Guangdong Laboratory)

Postdoctoral Position – Glioma Epigenomic Research (NIH National Cancer Institute)

Postdoctoral Fellow – RAS Proteins and Cancer Cell Stemness (University of Luxembourg)

Postdoctoral Position – Leukemia and Cancer Stemness (Moores Cancer Center, UC San Diego)

Research Fellow – Leukemia Stem Cell Research (Dana Farber Cancer Institute)

Postdoctoral Fellow – Breast Cancer Stem Cells (Albert Einstein College of Medicine)

Postdoctoral Scientist – Stem Cell Biology in Leukemia (University of Manchester)

Postdoctoral Fellow Position – RAS Cancer Cell Biology (University of Luxembourg)

Postdoctoral Researcher – Cancer Cell Invasiveness and Cancer Stem Cells (Cancer Research Center of Lyon)

Postdoctoral Associate – Glioma Stem Cell Biology (Cornell University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.